BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9272559)

  • 1. Enzymatic basis for the lack of oxamniquine activity in Schistosoma haematobium infections.
    Pica-Mattoccia L; Novi A; Cioli D
    Parasitol Res; 1997; 83(7):687-9. PubMed ID: 9272559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?
    Rugel AR; Guzman MA; Taylor AB; Chevalier FD; Tarpley RS; McHardy SF; Cao X; Holloway SP; Anderson TJC; Hart PJ; LoVerde PT
    Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():8-15. PubMed ID: 32315953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of tegumental damage to Schistosoma mansoni and S. haematobium after in vitro exposure to ferrocenyl, ruthenocenyl and benzyl derivatives of oxamniquine using scanning electron microscopy.
    Buchter V; Hess J; Gasser G; Keiser J
    Parasit Vectors; 2018 Nov; 11(1):580. PubMed ID: 30400935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for hycanthone drug action in schistosome parasites.
    Guzman M; Rugel A; Tarpley RS; Cao X; McHardy SF; LoVerde PT; Taylor AB
    Mol Biochem Parasitol; 2020 Mar; 236():111257. PubMed ID: 32027942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mode of action of oxamniquine and related schistosomicidal drugs.
    Pica-Mattoccia L; Cioli D
    Am J Trop Med Hyg; 1985 Jan; 34(1):112-8. PubMed ID: 3838223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on some derivatives of oxamniquine.
    el-Hamouly W; Pica-Mattoccia L; Cioli D; Schwartz HM; Archer S
    J Med Chem; 1988 Aug; 31(8):1629-31. PubMed ID: 3398000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of oxamniquine to the DNA of schistosomes.
    Pica-Mattoccia L; Cioli D; Archer S
    Trans R Soc Trop Med Hyg; 1989; 83(3):373-6. PubMed ID: 2617584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of drug resistant isolates of Schistosoma mansoni to antischistosomal agents.
    Drescher KM; Rogers EJ; Bruce JI; Katz N; Dias LC; Coles GC
    Mem Inst Oswaldo Cruz; 1993; 88(1):89-95. PubMed ID: 8246759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene.
    Pica-Mattoccia L; Dias LC; Moroni R; Cioli D
    Exp Parasitol; 1993 Dec; 77(4):445-9. PubMed ID: 8253157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schistosoma mansoni: hycanthone/oxamniquine resistance is controlled by a single autosomal recessive gene.
    Cioli D; Pica-Mattoccia L; Moroni R
    Exp Parasitol; 1992 Dec; 75(4):425-32. PubMed ID: 1493874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferrocenyl, Ruthenocenyl, and Benzyl Oxamniquine Derivatives with Cross-Species Activity against Schistosoma mansoni and Schistosoma haematobium.
    Hess J; Panic G; Patra M; Mastrobuoni L; Spingler B; Roy S; Keiser J; Gasser G
    ACS Infect Dis; 2017 Sep; 3(9):645-652. PubMed ID: 28686009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A human strain of Schistosoma mansoni resistant to schistosomicides].
    Dias LC; Pedro RJ; Rigo E; Goto MM; Mafra GL
    Rev Saude Publica; 1978 Mar; 12(1):110. PubMed ID: 675134
    [No Abstract]   [Full Text] [Related]  

  • 13. [Genetic and molecular aspects of drug resistance in Schistosoma mansoni].
    Pica L; Cioli D
    Ann Ist Super Sanita; 1986; 22(1):153-5. PubMed ID: 3752792
    [No Abstract]   [Full Text] [Related]  

  • 14. Stability of Schistosoma mansoni progeny to antischistosomal drugs.
    Dias LC; Olivier CE
    Rev Inst Med Trop Sao Paulo; 1985; 27(4):186-9. PubMed ID: 3832339
    [No Abstract]   [Full Text] [Related]  

  • 15. Schistosoma mansoni: chemotherapy of infections of different ages.
    Sabah AA; Fletcher C; Webbe G; Doenhoff MJ
    Exp Parasitol; 1986 Jun; 61(3):294-303. PubMed ID: 3086114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimentally produced resistance of Schistosoma mansoni to hycanthone.
    Jansma WB; Rogers SH; Liu CL; Bueding E
    Am J Trop Med Hyg; 1977 Sep; 26(5 Pt 1):926-36. PubMed ID: 907054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxamniquine in the treatment of various schistosome infections in South Africa.
    Pitchford RJ; Lewis M
    S Afr Med J; 1978 Apr; 53(17):677-80. PubMed ID: 354047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of in vitro RNA synthesis by hycanthone, oxamniquine and praziquantel.
    Wong LJ; Tsao GC; Bruce JI; Wong SS
    Experientia; 1990 May; 46(5):461-4. PubMed ID: 1693342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal hepatic necrosis in association with hycanthone.
    Hatchuel W
    S Afr Med J; 1978 Nov; 54(20):808. PubMed ID: 741319
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents.
    de Souza Dias LC; de Jesus Pedro R; Deberaldini ER
    Trans R Soc Trop Med Hyg; 1982; 76(5):652-9. PubMed ID: 7179419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.